Imfinzi Earns FDA Priority Review for Lung Cancer

AstraZeneca's cancer drug Imfinzi has been granted priority review by the U.S. Food and Drug Administration (FDA) for patients with limited-stage small cell lung cancer. The FDA's decision is anticipated in the fourth quarter of 2024. This follows the drug's positive late-stage data, demonstrating its effectiveness in improving overall survival and progression-free survival in patients whose disease has not progressed after platinum-based concurrent chemoradiotherapy.

Additionally, AstraZeneca recently received Breakthrough Therapy Designation from the FDA for Imfinzi in the same setting, aimed at accelerating the regulatory review process. The announcement comes as AstraZeneca's shares reached a record high of 130.48 pounds, solidifying its position as London's most valuable listed company.